<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cannabinoid CB(2) Receptor (CB(2)) activation has been shown to have immunomodulatory properties without psychotropic effects </plain></SENT>
<SENT sid="1" pm="."><plain>The hypothesis of this study is that selective CB(2) <z:chebi fb="4" ids="48705">agonist</z:chebi> treatment can attenuate <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>/reperfusion injury </plain></SENT>
<SENT sid="2" pm="."><plain>Selective CB(2) <z:chebi fb="4" ids="48705">agonists</z:chebi> (O-3853, O-1966) were administered intravenously 1 h before transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) or 10 mins after reperfusion in male mice </plain></SENT>
<SENT sid="3" pm="."><plain>Leukocyte/endothelial interactions were evaluated before MCAO, 1 h after MCAO, and 24 h after MCAO via a closed cranial window </plain></SENT>
<SENT sid="4" pm="."><plain>Cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and motor function were determined 24 h after MCAO </plain></SENT>
<SENT sid="5" pm="."><plain>Administration of the selective CB(2) <z:chebi fb="4" ids="48705">agonists</z:chebi> significantly decreased <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> (30%) and improved motor function (P&lt;0.05) after 1 h MCAO followed by 23 h reperfusion in mice </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0022118" disease_type="Disease or Syndrome" abbrv="">Transient ischemia</z:e> in untreated animals was associated with a significant increase in leukocyte rolling and <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> on both venules and arterioles (P&lt;0.05), whereas the enhanced rolling and <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> were attenuated by both selective CB(2) <z:chebi fb="4" ids="48705">agonists</z:chebi> administered either at 1 h before or after MCAO (P&lt;0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>CB(2) activation is associated with a reduction in white blood cell rolling and <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> along cerebral vascular endothelial cells, a reduction in <z:mpath ids='MPATH_124'>infarct</z:mpath> size, and improved motor function after transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
</text></document>